Any current/future new fundraising through debt or equity?

The company plans a Greenfield expansion at Tarapur with an expected CAPEX of Rs. 100 crores. This CAPEX will be funded through a mix of debt and internal accruals. No specific mention of new equity fundraising or IPO plans related to this expansion. The company is currently net debt-free, indicating a strong balance sheet to support funding. The Board has decided to proceed with listing on the NSE, with the listing process expected to complete within 6-8 months, but this is not explicitly linked to fresh fundraising.

Any current/future capex/capital investment/strategic investment?

Macrotech expansion: Rs. 28 crores already incurred; awaiting final approvals; expected commercialization in next few weeks; will increase intermediate manufacturing capacity and contribute to revenues from Q4 onwards. Greenfield expansion at Tarapur: Planned Capex of Rs. 100 crores, bringing 50% capacity addition; approvals and land are in place; construction to start soon (contractor selection in progress); expected to commercialize and start production by mid FY24. Expansion funded through mix of debt and internal accruals. Aim to increase outsourced production to 15%. Ongoing efforts in de

Future growth expectations in sales/revenue/volumes?

The company anticipates consistent growth over the next 3-5 years by adding new products from their existing pipeline. Plans to commercialize 3 new products this year and 3-4 products next calendar year, aiming for a product basket of 27-30 within two years. Targets to reach a quarterly revenue run rate of Rs. 100-110 crores within the next two to two-and-a-half years, driven by increased outsourcing, Macrotech expansion, and process debottlenecking. Greenfield expansion at Tarapur (50% capacity addition) expected to commercialize by mid-FY24, funded by Rs. 100 crores CAPEX. Market opportuniti

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects to reach a quarterly revenue run rate of around ₹100-110 crores within the next two years, driven by Macrotech expansion, increased outsourcing, and debottlenecking efforts. EBITDA margins currently at about 23%, with potential downside of up to 5% if raw material prices remain high; margins expected to recover quickly if prices stabilize. Long-term margin range anticipated between 18-25%, influenced more by macroeconomic factors than internal changes. Net profit for Q2 FY22 was ₹14 crores with an 18% margin; future margins may stay under pressure for the next four qu

Current/ Expected Orderbook/ Pending Orders?

The company does not explicitly mention a specific current order book value in the transcript. Rahul Nachane indicates strong and growing demand, with no risk of losing orders due to capacity constraints. They are increasing outsourcing and expanding capacity (Macrotech expansion and Greenfield project) to meet demand. Outsourcing optimization expected around May/June next year. Aim to reach approximately Rs. 100 crore quarterly run rate in 2 to 2.5 years, indicating a robust order pipeline. Confident about continuing sales growth and market share gains. They have sufficient capacity levers an

NGL Fine Chem LtdQ2 FY22Pharmaceuticals & Biotechnology

NGL Fine Chem Ltd Q2 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,612.8P/E: 32.0Market Cap: ₹1.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company anticipates consistent growth over the next 3-5 years by adding new products from their existing pipeline.
Plans to commercialize 3 new products this year and 3-4 products next calendar year, aiming for a product basket of 27-30 within two years.
Targets to reach a quarterly revenue run rate of Rs. 100-110 crores within the next two to two-and-a-half years, driven by increased outsourcing, Macrotech expansion, and process debottlenecking.
Greenfield expansion at Tarapur (50% capacity addition) expected to commercialize by mid-FY24, funded by Rs. 100 crores CAPEX.
Market opportunities for top 10 products estimated at Rs. 400-500 crores annually.
Focus remains on niche molecules with sufficient pipeline to keep growth intact.
Confident of maintaining and growing market share in key products and geographies including Latin America, Africa, and the US.

Margin guidance

Category 3

The company expects to reach a quarterly revenue run rate of around ₹100-110 crores within the next two years, driven by Macrotech expansion, increased outsourcing, and debottlenecking efforts.
EBITDA margins currently at about 23%, with potential downside of up to 5% if raw material prices remain high; margins expected to recover quickly if prices stabilize.
Long-term margin range anticipated between 18-25%, influenced more by macroeconomic factors than internal changes.
Net profit for Q2 FY22 was ₹14 crores with an 18% margin; future margins may stay under pressure for the next four quarters due to high costs.
The company plans a ₹100 crore Greenfield expansion at Tarapur, expected to add 50% capacity by mid-FY24, supporting further growth.
Overall, with strong demand and capacity expansions, sustained profit growth and stable margins are expected over the medium term.

See what NGL Fine Chem Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company plans a Greenfield expansion at Tarapur with an expected CAPEX of Rs. 100 crores.
This CAPEX will be funded through a mix of debt and internal accruals.
No specific mention of new equity fundraising or IPO plans related to this expansion.
The company is currently net debt-free, indicating a strong balance sheet to support funding.
The Board has decided to proceed with listing on the NSE, with the listing process expected to complete within 6-8 months, but this is not explicitly linked to fresh fundraising.

Order book

Yes

The company does not explicitly mention a specific current order book value in the transcript.
Rahul Nachane indicates strong and growing demand, with no risk of losing orders due to capacity constraints.
They are increasing outsourcing and expanding capacity (Macrotech expansion and Greenfield project) to meet demand.
Outsourcing optimization expected around May/June next year.
Aim to reach approximately Rs. 100 crore quarterly run rate in 2 to 2.5 years, indicating a robust order pipeline.
Confident about continuing sales growth and market share gains.
They have sufficient capacity levers and do not anticipate supply issues impacting order fulfillment.

See what NGL Fine Chem Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Macrotech expansion: Rs. 28 crores already incurred; awaiting final approvals; expected commercialization in next few weeks; will increase intermediate manufacturing capacity and contribute to revenues from Q4 onwards.
Greenfield expansion at Tarapur: Planned Capex of Rs. 100 crores, bringing 50% capacity addition; approvals and land are in place; construction to start soon (contractor selection in progress); expected to commercialize and start production by mid FY24.
Expansion funded through mix of debt and internal accruals.
Aim to increase outsourced production to 15%.
Ongoing efforts in debottlenecking and process improvements to drive near-term growth.
Construction costs initially higher due to metal and equipment price increases; expected to moderate as metal prices stabilize.

Track NGL Fine Chem Ltd — get its next earnings analysis in your feed

How does NGL Fine Chem Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisNGL Fine Chem Ltd

Rev 2Mar 3

See where NGL Fine Chem Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does NGL Fine Chem Ltd rank in Pharmaceuticals & Biotechnology?

Compare NGL Fine Chem Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What NGL Fine Chem Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →